4D pharma has appointed Prof Axel Glasmacher as Non-Executive Chairperson of the Board, with immediate effect.
Glasmacher joined the Board of 4D Pharma as a Non-Executive Director in January 2019. Previously, he was Senior Vice President and Head of the Global Clinical Research and Development Hematology Oncology at Celgene, where he worked in various global roles for more than 10 years. His work at Celgene led to the approvals of Revlimid(R), IdhifaR), and VidazaR) (haematological cancers). He also worked on the PD-L1 inhibitor durvalumab. Prior to Celgene, Professor Glasmacher worked within the fields of hematology-oncology at the University Hospital in Bonn.
David Norwood, the current Non-Executive Chairperson, will concurrently step down from this role but remains as a Non-Executive Director of 4D.
"4D is a company that has done excellent scientific and clinical work and is looking forward to important data readouts in the near future," said Prof. Glasmacher, Chairperson, 4D Pharma. "I am honored to work with investors, the board and the team at 4D to bring live biotherapeutic agents to patients as soon as possible."
"I am very pleased to report that Axel has taken up the position of Chairperson," said Duncan Peyton, CEO, 4D Pharma. "Since joining 4D's Board of Directors, Axel has made a significant contribution to the development of the Company's strategy. In addition, his expertise and track record in Oncology is highly complementary to our focus going forward. I would also like to thank Dave Norwood for his significant contribution to 4D as Chairperson, a role he has held since the formation of the Company, and I look forward to continuing to work with him in his role as a Non-Executive Director."
